John Mon, COO of Medifocus, Inc., Is Featured in an Audio Interview on Princeton Research's Money Info Show Hosted by Bill

John Mon, COO of Medifocus, Inc., Is Featured in an Audio Interview on 
Princeton Research's Money Info Show Hosted by Bill Chippas and
Charles Moskowitz 
Initiates On-Going Effort to Increase Investor Awareness 
COLUMBIA, MD and TORONTO -- (Marketwired) -- 08/12/13 --  Medifocus,
Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that an
audio interview with John Mon, COO of Medifocus, Inc. (TSX VENTURE:
MFS) (OTCQX: MDFZF), with Charles Moskowitz of the "Money Info Show
hosted by Bill Chippas" is now available and can be heard at 
The Money Info Show airs at 10:00AM to 11:00AM EDT every Tuesday and
can be heard at 
Last week, John was the featured speaker on Small Cap which
can be heard at 
John discussed the recent news for the Company, the business models
and markets for their technologies, in addition to the goals of
Medifocus in 2013, and beyond. 
"We are excited about our current position in the BPH market and are
extremely optimistic about moving forward in Phase III with our
breast cancer treatment technology," explained John Mon. "We are
working to sustain and increase shareholder value through executing
on our accelerated growth model in 2013 and beyond."  
Mr. Mon was previously V.P. of business and product development,
General Manager, and Director of Celsion. He achieved FDA approvals
for IDE/PMA/510K submissions, and has worked with clinicians,
engineers, and patent attorneys on thermotherapy and
breast-cancer-related devices. Mr. Mon has co-authored several
scholarly articles and holds many granted and pending patents in the
area of thermotherapy for the treatment of cancer and other diseases. 
Get More Corporate and Stock Quote information at: 
See Medifocus Corporate Fact Sheet March 2013: 
Visit the corporate web site: 
About Medifocus, Inc.
 Medifocus, Inc. owns two fully developed
technology platforms with comprehensive US and international patent
protection: (1) The Endo-thermotherapy Platform-a catheter-basis
focused heat technology platform that utilizes natural body openings
to deliver precise microwave thermotherapy to the diseased sites. The
U.S. FDA approved Prolieve Thermodilatation System for the treatment
of Benign Prostatic Hyperplasia ("BPH") was developed based on the
Endo-thermotherapy and is currently generating revenue, and (2) The
Adaptive Phased Array (APA) Microwave Focusing Platform-invented by
MIT, licensed to Medifocus, directs precisely focused microwave
energy at tumor center to induce shrinkage or eradication of tumors
without undue harm to surrounding tissue. The Company's APA 1000
Breast Cancer Treatment System, developed from the APA technology
platform has received approval from the U.S. FDA and Health Canada to
conduct the pivotal Phase III clinical trials. The Company believes
that these two technology platforms can provide the design basis for
the development of multiple cancer treatment systems for surface,
subsurface and deep seated localized and regional cancers. Please
visit, and
for more details. 
About Princeton Research
 Princeton Research Inc. of Nevada publishes
the Market Strategies Newsletter to provide investors access to our
proven Balanced Investing stocks, ETFs and options trading
techniques, which provide portfolio protection while generating high
return investing in up or down markets. 
Princeton Research also provides a full array of effective investment
relations services designed to benefit all types of publicly traded
companies. They strive to maximize shareholder value -- working to
facilitate the most effective communication between your company and
the greater investment community. 
Forward-Looking Statements
 This management's discussion and analysis
may contain statements that are "Forward-looking Statements". These
include statements about the Company's expectations, beliefs, plans,
objectives and assumptions about future events or performance. These
statements are often, but not always, made through the use of words
or phrases such as "will likely result," "are expected to," "will
continue," "anticipate," "believes," "estimate," "intend," "plan,"
"would," and "outlook" or statements to the effect that actions,
events or results "will," "may," "should" or "would" be taken, occur
or be achieved. Forward-looking statements are not historical facts,
and are subject to a number of risks and uncertainties beyond the
Company's control. Accordingly, the Company's actual results could
differ materially from those suggested by these forward-looking
statements for various reasons discussed throughout this analysis.
Forward-looking statements are made on the basis of the beliefs,
opinions, and estimates of the Company's management on the date the
statements are made and, other than in compliance with applicable
securities laws, the Company does not undertake any obligation to
update forward-looking statements if the circumstances or
management's beliefs, opinions or estimates should change. Readers
should not place undue reliance on forward-looking statements. 
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release. 
Medifocus, Inc.
John Mon
Investor Relations: 
Robert Giordano 
Consulting for Strategic Growth 
Princeton Research
Charles Moskowitz
Stuart T. Smith